{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:46:26Z","timestamp":1794469586583,"version":"4.9.1"},"reference-count":90,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,29]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple causes (pseudothrombocytopenia, hemodilution, increased consumption, decreased production, increased sequestration, and immune-mediated destruction of platelets) alone or in combination make thrombocytopenia very common in intensive care unit (ICU) patients. Persisting thrombocytopenia in critically ill patients is associated with, but not causative of, increased mortality. Identification of the underlying cause is key for management decisions in individual patients. While platelet transfusion might be indicated in patients with impaired platelet production or increased platelet destruction, it could be deleterious in patients with increased intravascular platelet activation. Sepsis and trauma are the most common causes of thrombocytopenia in the ICU. In these patients, treatment of the underlying disease will also increase platelet counts. Heparin-induced thrombocytopenia requires alternative anticoagulation at a therapeutic dose and immune thrombocytopenia immunomodulatory treatment. Thrombocytopenia with symptomatic bleeding at or above World Health Organization grade 2 or planned invasive procedures are established indications for platelet transfusions, while the evidence for a benefit of prophylactic platelet transfusions is weak and controversial. If the platelet count does not increase after transfusion of 2 fresh ABO blood group\u2013identical platelet concentrates (therapeutic units), ongoing platelet consumption and high-titer anti-HLA class I antibodies should be considered. The latter requires transfusion of HLA-compatible platelet concentrates.<\/jats:p>","DOI":"10.1182\/blood-2016-09-693655","type":"journal-article","created":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T13:44:57Z","timestamp":1478785497000},"page":"3032-3042","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":81,"title":["How I evaluate and treat thrombocytopenia in the intensive care unit patient"],"prefix":"10.1182","volume":"128","author":[{"given":"Andreas","family":"Greinacher","sequence":"first","affiliation":[{"name":"Institute of Immunology and Transfusion Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixten","family":"Selleng","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University Medicine Greifswald, Greifswald, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111614093071500_B1","doi-asserted-by":"crossref","article-title":"Thrombocytopenia in the intensive care unit patient","author":"Greinacher","DOI":"10.1182\/asheducation-2010.1.135"},{"issue":"2","key":"2019111614093071500_B2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1378\/chest.10-2243","article-title":"The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review","volume":"139","author":"Hui","year":"2011","journal-title":"Chest"},{"issue":"5","key":"2019111614093071500_B3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1055\/s-0031-1287873","article-title":"Hematologic failure","volume":"32","author":"Levi","year":"2011","journal-title":"Semin Respir Crit Care Med"},{"key":"2019111614093071500_B4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/B978-0-12-387837-3.00003-1","article-title":"The regulation of platelet life span","volume-title":"Platelets","author":"Josefsson","year":"2013"},{"issue":"4","key":"2019111614093071500_B5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1053\/j.seminhematol.2011.08.002","article-title":"A rational approach to the diagnosis and management of thrombocytopenia in the hospitalized patient","volume":"48","author":"Arnold","year":"2011","journal-title":"Semin Hematol"},{"issue":"1","key":"2019111614093071500_B6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nm.3770","article-title":"The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling","volume":"21","author":"Grozovsky","year":"2015","journal-title":"Nat Med"},{"issue":"2","key":"2019111614093071500_B7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.annepidem.2005.06.052","article-title":"Platelet counts differ by sex, ethnicity, and age in the United States","volume":"16","author":"Segal","year":"2006","journal-title":"Ann Epidemiol"},{"issue":"4","key":"2019111614093071500_B8","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/00003246-200204000-00005","article-title":"Time course of platelet counts in critically ill patients","volume":"30","author":"Akca","year":"2002","journal-title":"Crit Care Med"},{"issue":"4","key":"2019111614093071500_B9","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1378\/chest.104.4.1243","article-title":"Thrombocytopenia in the intensive care unit","volume":"104","author":"Baughman","year":"1993","journal-title":"Chest"},{"issue":"2","key":"2019111614093071500_B10","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jinf.2007.01.011","article-title":"Impact of thrombocytopenia on outcome of patients admitted to ICU for severe community-acquired pneumonia","volume":"55","author":"Brogly","year":"2007","journal-title":"J Infect"},{"issue":"4","key":"2019111614093071500_B11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jcrc.2005.09.008","article-title":"Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors","volume":"20","author":"Crowther","year":"2005","journal-title":"J Crit Care"},{"issue":"5","key":"2019111614093071500_B12","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1378\/chest.115.5.1363","article-title":"Thrombocytopenia in a surgical ICU","volume":"115","author":"St\u00e9phan","year":"1999","journal-title":"Chest"},{"issue":"8","key":"2019111614093071500_B13","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1097\/00003246-200208000-00015","article-title":"Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome","volume":"30","author":"Strauss","year":"2002","journal-title":"Crit Care Med"},{"issue":"6","key":"2019111614093071500_B14","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1097\/00003246-200006000-00031","article-title":"Thrombocytopenia and prognosis in intensive care","volume":"28","author":"Vanderschueren","year":"2000","journal-title":"Crit Care Med"},{"issue":"1","key":"2019111614093071500_B15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.hrtlng.2009.07.005","article-title":"Thrombocytopenia and outcome in critically ill patients with bloodstream infection","volume":"39","author":"Vandijck","year":"2010","journal-title":"Heart Lung"},{"issue":"3","key":"2019111614093071500_B16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.seminhematol.2013.06.008","article-title":"Thrombocytopenia in the intensive care unit-diagnostic approach and management","volume":"50","author":"Thiele","year":"2013","journal-title":"Semin Hematol"},{"issue":"4","key":"2019111614093071500_B17","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/cc4975","article-title":"Coagulation abnormalities in critically ill patients","volume":"10","author":"Levi","year":"2006","journal-title":"Crit Care"},{"issue":"25","key":"2019111614093071500_B18","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1182\/blood-2012-04-420661","article-title":"Bacteria differentially induce degradation of Bcl-xL, a survival protein, by human platelets","volume":"120","author":"Kraemer","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2019111614093071500_B19","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1084\/jem.168.2.527","article-title":"Staphylococcal alpha toxin promotes blood coagulation via attack on human platelets","volume":"168","author":"Bhakdi","year":"1988","journal-title":"J Exp Med"},{"issue":"6","key":"2019111614093071500_B20","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1046\/j.1537-2995.2003.00407.x","article-title":"Platelet transfusion and thrombotic thrombocytopenic purpura","volume":"43","author":"McCarthy","year":"2003","journal-title":"Transfusion"},{"issue":"9","key":"2019111614093071500_B21","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/blood-2014-10-605493","article-title":"Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality","volume":"125","author":"Goel","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2019111614093071500_B22","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJMra043442","article-title":"Diagnosis from the blood smear","volume":"353","author":"Bain","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111614093071500_B23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.5482\/HAMO-13-01-0003","article-title":"My patient is thrombocytopenic! Is (s)he? Why? And what shall I do? A practical approach to thrombocytopenia","volume":"33","author":"Alberio","year":"2013","journal-title":"Hamostaseologie"},{"issue":"2","key":"2019111614093071500_B24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ajh.2830500206","article-title":"EDTA-dependent pseudothrombocytopenia: a clinical and epidemiological study of 112 cases, with 10-year follow-up","volume":"50","author":"Bizzaro","year":"1995","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111614093071500_B25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0735-1097(00)00688-4","article-title":"Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy","volume":"36","author":"Sane","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2019111614093071500_B26","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.amjcard.2003.12.051","article-title":"Final results of the ReoPro readministration registry","volume":"93","author":"Dery","year":"2004","journal-title":"Am J Cardiol"},{"issue":"2","key":"2019111614093071500_B27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00392-006-0459-7","article-title":"Glycoprotein IIb\/IIIa inhibitor-induced thrombocytopenia: diagnosis and treatment","volume":"96","author":"Said","year":"2007","journal-title":"Clin Res Cardiol"},{"key":"2019111614093071500_B28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.thromres.2016.02.022","article-title":"Sepsis-associated thrombocytopenia","volume":"141","author":"Larkin","year":"2016","journal-title":"Thromb Res"},{"issue":"24","key":"2019111614093071500_B29","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/blood-2015-11-680744","article-title":"Thrombocytopenia is associated with a dysregulated host response in critically ill sepsis patients","volume":"127","author":"Claushuis","year":"2016","journal-title":"Blood"},{"key":"2019111614093071500_B30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jcrc.2015.11.010","article-title":"Thrombocytopenia is associated with a dysregulated host response in critically ill sepsis patients","volume":"32","author":"Tsirigotis","year":"2016","journal-title":"J Crit Care"},{"issue":"4","key":"2019111614093071500_B31","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/CCM.0000000000001520","article-title":"Is thrombocytopenia an early prognostic marker in septic shock?","volume":"44","author":"Thiery-Antier","year":"2016","journal-title":"Crit Care Med"},{"issue":"2","key":"2019111614093071500_B32","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/CCM.0b013e31827e83af","article-title":"Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012","volume":"41","author":"Dellinger","year":"2013","journal-title":"Crit Care Med"},{"issue":"3","key":"2019111614093071500_B33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7326\/M14-1589","article-title":"Platelet transfusion: a clinical practice guideline from the AABB","volume":"162","author":"Kaufman","year":"2015","journal-title":"Ann Intern Med"},{"issue":"2","key":"2019111614093071500_B34","first-page":"360","article-title":"Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates","volume":"81","author":"Hiippala","year":"1995","journal-title":"Anesth Analg"},{"issue":"3","key":"2019111614093071500_B35","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/01.TA.0000053245.08642.1F","article-title":"Minimizing dilutional coagulopathy in exsanguinating hemorrhage: a computer simulation","volume":"54","author":"Hirshberg","year":"2003","journal-title":"J Trauma"},{"key":"2019111614093071500_B36","doi-asserted-by":"crossref","article-title":"The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition","author":"Rossaint","DOI":"10.1186\/s13054-016-1265-x"},{"issue":"2","key":"2019111614093071500_B37","doi-asserted-by":"crossref","first-page":"R76","DOI":"10.1186\/cc12685","article-title":"Management of bleeding and coagulopathy following major trauma: an updated European guideline","volume":"17","author":"Spahn","year":"2013","journal-title":"Crit Care"},{"issue":"2","key":"2019111614093071500_B38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/ALN.0000000000000463","article-title":"Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management*","volume":"122","author":"American Society of Anesthesiologists Task Force on Perioperative Blood Management","year":"2015","journal-title":"Anesthesiology"},{"key":"2019111614093071500_B39","volume-title":"International ATLS working group. Advanced trauma life support (ATLS\u00ae): the ninth edition","author":"ATLS Subcommittee; American College of Surgeons\u2019 Committee on Trauma","year":"2013"},{"key":"2019111614093071500_B40","author":"National Clinical Guideline Centre (UK)"},{"issue":"9734","key":"2019111614093071500_B41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(10)60835-5","article-title":"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial","volume":"376","author":"Shakur","year":"2010","journal-title":"Lancet"},{"key":"2019111614093071500_B42","article-title":"The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial","author":"Roberts"},{"issue":"5","key":"2019111614093071500_B43","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1177\/1076029614526639","article-title":"Immune thrombocytopenia: recent progress in pathophysiology and treatment","volume":"21","author":"Abadi","year":"2015","journal-title":"Clin Appl Thromb Hemost"},{"issue":"16","key":"2019111614093071500_B44","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"issue":"9300","key":"2019111614093071500_B45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(02)07275-6","article-title":"Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial","volume":"359","author":"Godeau","year":"2002","journal-title":"Lancet"},{"issue":"suppl 2","key":"2019111614093071500_B46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000356910","article-title":"[Immune thrombocytopenia -- onkopedic guidelines update: recommendations of a joint working group of the DGHO, \u00d6GHO, SGH + SSH and GPOH]","volume":"37","author":"Matzdorff","year":"2014","journal-title":"Oncol Res Treat"},{"issue":"1","key":"2019111614093071500_B47","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1586\/ehm.10.76","article-title":"Current treatment options for primary immune thrombocytopenia","volume":"4","author":"Salama","year":"2011","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"2019111614093071500_B48","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1055\/s-0031-1273090","article-title":"Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature","volume":"37","author":"Tufano","year":"2011","journal-title":"Semin Thromb Hemost"},{"issue":"9","key":"2019111614093071500_B49","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/jth.12338","article-title":"Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH","volume":"11","author":"Carrier","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"17","key":"2019111614093071500_B50","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1200\/JCO.2013.49.1118","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"31","author":"Lyman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111614093071500_B51","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3324\/haematol.2009.018390","article-title":"Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database","volume":"95","author":"Sarpatwari","year":"2010","journal-title":"Haematologica"},{"key":"2019111614093071500_B52","author":"Gould"},{"issue":"12","key":"2019111614093071500_B53","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood-2016-03-603365","article-title":"How I treat refractory immune thrombocytopenia","volume":"128","author":"Cuker","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2019111614093071500_B54","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMct1014202","article-title":"Thrombopoietin-receptor agonists for primary immune thrombocytopenia","volume":"365","author":"Imbach","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111614093071500_B55","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/ejh.12181","article-title":"Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials","volume":"91","author":"Rodeghiero","year":"2013","journal-title":"Eur J Haematol"},{"issue":"4","key":"2019111614093071500_B56","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1538-7836.2006.01787.x","article-title":"Evaluation of pretest clinical score (4 T\u2019s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings","volume":"4","author":"Lo","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2019111614093071500_B57","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/j.1538-7836.2007.02617.x","article-title":"Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4\/heparin antibodies of the IgG, IgM, and IgA classes","volume":"5","author":"Greinacher","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"12","key":"2019111614093071500_B58","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1111\/j.1538-7836.2011.04536.x","article-title":"Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis","volume":"9","author":"Warkentin","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2019111614093071500_B59","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1592\/phco.21.17.1325.34418","article-title":"Prevalence and risk of thrombocytopenia with valproic acid: experience at a psychiatric teaching hospital","volume":"21","author":"Conley","year":"2001","journal-title":"Pharmacotherapy"},{"issue":"4","key":"2019111614093071500_B60","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1378\/chest.13-0121","article-title":"Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes","volume":"144","author":"Williamson","year":"2013","journal-title":"Chest"},{"issue":"6","key":"2019111614093071500_B61","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1378\/chest.08-2534","article-title":"Coagulopathy in critically ill patients: part 1: platelet disorders","volume":"136","author":"Rice","year":"2009","journal-title":"Chest"},{"issue":"6 suppl","key":"2019111614093071500_B62","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1097\/CCM.0b013e3181de0b88","article-title":"Drug-induced thrombocytopenia in critically ill patients","volume":"38","author":"Priziola","year":"2010","journal-title":"Crit Care Med"},{"issue":"5","key":"2019111614093071500_B63","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/0897190014546099","article-title":"Drug-induced immune thrombocytopenia","volume":"27","author":"Kam","year":"2014","journal-title":"J Pharm Pract"},{"issue":"2","key":"2019111614093071500_B64","doi-asserted-by":"crossref","first-page":"55","DOI":"10.21307\/immunohematology-2019-099","article-title":"Drug-induced immune thrombocytopenia: incidence, clinical features, laboratory testing, and pathogenic mechanisms","volume":"30","author":"Curtis","year":"2014","journal-title":"Immunohematology"},{"issue":"3","key":"2019111614093071500_B65","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tmrv.2013.05.005","article-title":"Approach to the diagnosis and management of drug-induced immune thrombocytopenia","volume":"27","author":"Arnold","year":"2013","journal-title":"Transfus Med Rev"},{"issue":"7","key":"2019111614093071500_B66","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/pan.12174","article-title":"Valproic acid and acquired coagulopathy","volume":"23","author":"Abdallah","year":"2013","journal-title":"Paediatr Anaesth"},{"issue":"3","key":"2019111614093071500_B67","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1528-1167.2007.01429.x","article-title":"Valproate-induced thrombocytopenia: a prospective monotherapy study","volume":"49","author":"Nasreddine","year":"2008","journal-title":"Epilepsia"},{"issue":"4","key":"2019111614093071500_B68","first-page":"PCC.13l01526","article-title":"A case of thrombocytopenia associated with valproic Acid treatment","volume":"15","author":"Nerumalla","year":"2013","journal-title":"Prim Care Companion CNS Disord"},{"issue":"3","key":"2019111614093071500_B69","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/JCP.0b013e3181db2684","article-title":"Hematological effects of valproate in psychiatric patients: what are the risk factors?","volume":"30","author":"Vasudev","year":"2010","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"2019111614093071500_B70","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2019111614093071500_B71","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1182\/blood-2010-02-268326","article-title":"Drug-induced thrombocytopenia: development of a novel NOD\/SCID mouse model to evaluate clearance of circulating platelets by drug-dependent antibodies and the efficacy of IVIG","volume":"116","author":"Liang","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111614093071500_B72","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/jth.12852","article-title":"Recommendations for standardization of laboratory testing for drug-induced immune thrombocytopenia: communication from the SSC of the ISTH","volume":"13","author":"Arnold","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2019111614093071500_B73","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ccc.2011.08.001","article-title":"Heparin-induced thrombocytopenia in critically ill patients","volume":"27","author":"Warkentin","year":"2011","journal-title":"Crit Care Clin"},{"issue":"1","key":"2019111614093071500_B74","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1538-7836.2009.03626.x","article-title":"Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive","volume":"8","author":"Selleng","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2019111614093071500_B75","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1161\/01.CIR.95.5.1242","article-title":"Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery","volume":"95","author":"Bauer","year":"1997","journal-title":"Circulation"},{"issue":"11","key":"2019111614093071500_B76","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1111\/j.1538-7836.2005.01623.x","article-title":"Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3","volume":"3","author":"Lubenow","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2019111614093071500_B77","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1055\/s-0034-1398381","article-title":"Heparin-induced thrombocytopenia in critically ill patients","volume":"41","author":"Warkentin","year":"2015","journal-title":"Semin Thromb Hemost"},{"key":"2019111614093071500_B78","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1182\/asheducation-2007.1.172","article-title":"Evidence-based platelet transfusion guidelines","author":"Slichter","year":"2007","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"2","key":"2019111614093071500_B79","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/00001721-199603000-00027","article-title":"Activated platelets and impaired platelet function in intensive care patients analyzed by flow cytometry","volume":"7","author":"Lundahl","year":"1996","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"3-4","key":"2019111614093071500_B80","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/09537109876735","article-title":"Impaired platelet function correlates with multi-organ dysfunction. A study of patients with sepsis","volume":"9","author":"Lundahl","year":"1998","journal-title":"Platelets"},{"issue":"12","key":"2019111614093071500_B81","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/j.1538-7836.2004.01009.x","article-title":"Platelet function in sepsis","volume":"2","author":"Yaguchi","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2019111614093071500_B82","first-page":"433","article-title":"Effect of antibiotics on platelet thromboplastic function and thrombin activity","volume":"9","author":"Nakahara","year":"1978","journal-title":"J Med"},{"issue":"1","key":"2019111614093071500_B83","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1128\/AAC.9.1.91","article-title":"Influence of cephalosporin antibiotics on blood coagulation and platelet function","volume":"9","author":"Natelson","year":"1976","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2019111614093071500_B84","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0035-1547350","article-title":"Clinical Relevance and Practical Value of Platelet Function Assessment Using Multiple Electrode Aggregometry during Extracorporeal Circulation","volume":"63","author":"Petricevic","year":"2015","journal-title":"Thorac Cardiovasc Surg"},{"issue":"10","key":"2019111614093071500_B85","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1111\/j.1537-2995.2008.01822.x","article-title":"Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature","volume":"48","author":"Hopkins","year":"2008","journal-title":"Transfusion"},{"issue":"2","key":"2019111614093071500_B86","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/vox.12274","article-title":"Platelet transfusion in thrombotic thrombocytopenic purpura","volume":"109","author":"Otrock","year":"2015","journal-title":"Vox Sang"},{"issue":"8","key":"2019111614093071500_B87","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1182\/blood-2013-02-435693","article-title":"Platelet transfusions for critically ill patients with thrombocytopenia","volume":"123","author":"Lieberman","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2019111614093071500_B88","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000268058","article-title":"2. Platelet concentrates","volume":"36","author":"The Board of the German Medical Association on the Recommendation of the Scientific Advisory Board (Bundes\u00e4rztekammer)","year":"2009","journal-title":"Transfus Med Hemother"},{"issue":"6","key":"2019111614093071500_B89","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1046\/j.1537-2995.2001.41060766.x","article-title":"Platelet alloantibodies in transfused patients","volume":"41","author":"Kiefel","year":"2001","journal-title":"Transfusion"},{"issue":"10038","key":"2019111614093071500_B90","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/S0140-6736(16)30392-0","article-title":"Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial","volume":"387","author":"Baharoglu","year":"2016","journal-title":"Lancet"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/26\/3032\/1397455\/blood693655.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/26\/3032\/1397455\/blood693655.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T01:31:12Z","timestamp":1657675872000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/26\/3032\/116533\/How-I-evaluate-and-treat-thrombocytopenia-in-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,29]]},"references-count":90,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2016,12,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-09-693655","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,29]]}}}